现代检验医学杂志2024，Vol.39Issue(1)：1-4,105,5.DOI:10.3969/j.issn.1671-7414.2024.01.001
胃癌晚期患者CYP3A5*3基因多态性与阿帕替尼单药治疗不良反应的相关性研究
Correlation between CYP3A5*3 Gene Polymorphism and Adverse Reactions of Apatinib Monotherapy in Patients with Advanced Gastric Cancer
摘要
Abstract
Objective To investigate the relationship between cytochrome P450 3A5*3(CYP3A5*3)gene polymorphism and adverse reactions of apatinib monotherapy in advanced gastric cancer patients.Methods A total of 86 patients with advanced gastric cancer who received apatinib monotherapy at Nanjing First Hospital from January 2020 to June 2022 were selected,and 2 ml of peripheral venous blood from patients was collected.The genotype of CYP3A5*3 was identified using PCR-RFLP combined sequencing method,and its correlation with adverse reactions was analyzed by apatinib.Results Among the 86 patients,there were 29 cases of mutant heterozygous genotype(AG genotype)and 51 cases of mutant homozygous genotype(GG genotype),with a mutation type accounting for 93.02％.The incidence of hypertension and leukopenia in patients with the CYP3A5*3 GG genotype was significantly higher than in patients with the AA+AG genotype(χ2=6.154,6.947,P=0.043,0.027).Other adverse reactions related to apatinib treatment were not found to be associated with the CYP3A5*3 genotype(P＞0.05).In addition,no correlation was found between severe adverse reactions and the CYP3A5*3 genotype(P＞0.05).Conclusion The CYP3A5*3 GG genotype significantly increased the risk of hypertension and leukopenia caused by apatinib monotherapy,and no correlation was found with the risk of serious adverse reactions.关键词
细胞色素P450 3A5*3/基因多态性/胃癌/阿帕替尼/不良反应Key words
CYP3A5*3/gene polymorphism/gastric cancer/apatinib/adverse reaction分类
医药卫生引用本文复制引用
孟安娜,李杨..胃癌晚期患者CYP3A5*3基因多态性与阿帕替尼单药治疗不良反应的相关性研究[J].现代检验医学杂志,2024,39(1):1-4,105,5.基金项目
江苏省南京药学会常州四药医院药学科研项目(NO.2019YX013):CYP3A4*1G/18B及CYP3A5*3基因多态性对晚期胃癌患者阿帕替尼稳态血药浓度及不良反应影响的研究. （NO.2019YX013）
